Atrial fibrillation Magnesium sulfate atrial fibrillation CABG cardiac surgery
Conditions
Interventions
MgSO4 was re-
installed to new bottle without any label,
so,
all study personnel and
participants were blinded to treatment assignment for the duration of the study. bottle 1 is low dose of Magnesium sulfate 5 gm/25ml per bottle. The drug was mixed with
norma
all study personnel and
participants were blinded to treatment assignment for the duration of the study. bottle 2 is high dose of Magnesium sulfate 10 gm/25ml per bottle. The drug was mixed with
nor
Active Comparator Drug,Active Comparator Drug
Bottle 1,Bottle 2
Sponsors
No
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: coronary arterial disease that required elective coronary arterial bypass grafting operation without any exclusion criteria between August 2008 and Febuary 2012
Exclusion criteria
Exclusion criteria: Sick sinus syndrome 2nd or 3rd degree atrioventricular block history of AF any other surgical procedure during the current admissio Q-wave myocardial infarction in the preceding 6 weeks Ongoing treatment with amiodarone, digoxin or warfarin Permanent pacemaker implantation Valvular regurgitation Renal failure (serum creatinine > 2.0) Preoperative serum magnesium level > 4.0 mEq/dl
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of atrial fibrillation before discharge ECG monitoring | — |
Secondary
| Measure | Time frame |
|---|---|
| length of stay until discharge days of postoperative admission,length of ICU stay until discharge from ICU days of postoperative ICU stay,Cost of medical care until discharge total cost of hospital stay during same admission | — |
Contacts
Public ContactNoppon Taksaudom
Chiang Mai University
Outcome results
None listed